Pharsight

Lo Loestrin Fe generic

Lo Loestrin Fe is a contraceptive drug owned by Apil. It contains Ethinyl Estradiol and Norethindrone Acetate and is available in tablet form for oral administration. This drug was first authorised for market use on 21 October, 2010.

When will Lo Loestrin Fe generic be available?

The generic version of Lo Loestrin Fe could potentially be released after 02 February, 2029. This is due to the expiration of the drug's last patent (US7704984), titled 'Extended estrogen dosing contraceptive regimen', on that date.

Lo Loestrin Fe uses

Lo Loestrin Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. The effectiveness of this drug can be attributed to its active ingredients, Ethinyl Estradiol and Norethindrone Acetate, which work together to prevent ovulation and change the cervical mucus and uterine lining, making it harder for sperm to reach the uterus.

Lo Loestrin Fe patent expiration

Lo Loestrin Fe has a total of 1 drug patent, which is set to expire on 02 February, 2029. This patent (US7704984) is titled 'Extended estrogen dosing contraceptive regimen'. After the expiration date, the generic version of Lo Loestrin Fe may be available. Below are the details of the patent:

Litigations filed on Lo Loestrin Fe

Lo Loestrin Fe dosage

Want to ask something?